Welcome to our dedicated page for TELEFLEX SEC filings (Ticker: TFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teleflex Incorporated filings document the regulatory record for a medical technology issuer with global product categories in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Periodic and current reports disclose operating results, GAAP and non-GAAP measures, revenue adjustments, foreign-currency effects, acquisition and integration items, divestiture-related costs, reserves and other factors affecting reported performance.
Teleflex 8-K filings also cover material events, executive and board transitions, compensation arrangements, shareholder communications, material agreements, capital-structure disclosures and clinical or regulatory matters when reported. Proxy materials disclose director elections, board committee matters, executive compensation, equity awards, pay-versus-performance information and shareholder voting items.
Teleflex Executive Vice President & CFO John Deren reported new equity compensation awards and a small share disposition related to taxes. On March 3, 2026, he acquired 30,362 stock options and two Common Stock restricted stock unit awards totaling 13,784 shares, all granted at no cash cost.
According to the footnotes, one RSU award vests in four 25% installments on 3/3/2027, 3/3/2028, 3/3/2029 and 3/3/2030, and another vests 50% on each of 3/3/2027 and 9/3/2027, in each case subject to his continued service. A stock option grant vests in three equal annual installments on 3/3/2027, 3/3/2028 and 3/3/2029. On March 4, 2026, 229 Common shares were disposed of at $119.18 per share to cover tax withholding upon RSU vesting, leaving him with 18,073 directly held Common shares.
Teleflex Inc. corporate vice president and chief HR officer Cameron P. Hicks reported equity compensation and related tax withholding transactions. On March 3, 2026, he acquired 2,447 shares of common stock and 5,649 shares of common stock as restricted stock unit awards under the Teleflex Incorporated 2023 Stock Incentive Plan, along with a stock option for 16,133 shares. The RSU footnotes state that these awards vest in installments between March 3, 2027 and March 3, 2030, subject to his continued service, and the stock option vests in three annual tranches from March 3, 2027 through March 3, 2029. A separate transaction on March 4, 2026 shows 98 shares of common stock disposed at $119.18 per share to satisfy tax liabilities upon vesting of a restricted stock unit award, leaving 19,362.657 common shares held directly afterward. The filing also notes an indirect holding of 36.916 common shares in a 401(k) plan.
Teleflex Inc. corporate vice president James Winters reported new equity awards and a small share disposition related to taxes. On March 3, 2026, he was granted 21,510 stock options and two restricted stock unit awards of 3,262 and 9,745 common shares, all under the company’s 2023 Stock Incentive Plan.
The RSU awards vest over multiple dates between March 3, 2027 and March 3, 2030, subject to his continued service, while the stock options vest in three equal annual installments starting March 3, 2027. On March 4, 2026, 247 common shares were withheld at $119.18 per share to cover tax obligations upon RSU vesting, leaving him with 17,760 directly owned common shares.
Teleflex Inc. Executive Vice President & CFO John Deren reported a tax-related share disposition. On the vesting of restricted and performance stock units, 231 shares of common stock were withheld at $122.06 per share to satisfy tax liabilities, leaving him with 4,518 directly held shares and 4.377 shares held indirectly through a 401(k) trustee.
Teleflex Inc. corporate vice president and chief HR officer Cameron P. Hicks reported a tax-related share disposition. On February 28, 2026, 396 shares of common stock were withheld to satisfy tax liability upon vesting of restricted and performance stock unit awards at $122.06 per share. After this withholding, Hicks directly held 11,364.657 common shares and indirectly held 36.916 shares through a 401(k) trustee.
Teleflex Inc. executive Daniel V. Logue reported a tax-related share disposition. On the vesting of restricted and performance stock units, 484 shares of common stock were withheld to satisfy tax liabilities at a price of $122.06 per share. After this withholding, he holds 14,930.888 shares directly and 305.683 shares indirectly through a 401(k) trustee.
Teleflex Inc. corporate vice president of manufacturing and supply James Winters reported a Form 4 showing a tax-withholding disposition of 661 shares of common stock at $122.06 per share. The shares were withheld to satisfy tax liabilities on vested restricted and performance stock units, and Winters now directly holds 5,000 shares.
Teleflex Incorporated outlines a major strategic shift in this annual report. The company, a global provider of single-use medical devices for critical care and surgical applications, plans to sell its Acute Care, Interventional Urology and OEM businesses for $2.0 billion in cash, with approximately $1.5 billion expected for OEM and $530 million for Acute Care and IU. These transactions are subject to regulatory approvals and are targeted for completion in the second half of 2026.
After these divestitures, Teleflex will focus on vascular, emergency, interventional and surgical product lines across its Americas, EMEA and Asia segments. The company continues multi‑year footprint realignment and restructuring programs aimed at improving manufacturing and cost efficiency, and is upgrading its global ERP system.
Governance changes include the January 2026 departure of Chairman, President and CEO Liam J. Kelly and the appointment of director Stuart A. Randle as Interim President and CEO, with Stephen K. Klasko, M.D. becoming independent Chair. The filing also details extensive regulatory exposure, reimbursement pressures, intense competition, reliance on ethylene oxide sterilization, and execution risks around the strategic transformation.
Teleflex reported strong 2025 results from continuing operations while outlining a major portfolio transformation and restructuring tied to pending business divestitures. GAAP revenue from continuing operations was $1,992.7 million, up 17.2%, and adjusted revenue reached $1,983.7 million, up 16.3%.
GAAP diluted EPS from continuing operations was $1.31, while adjusted diluted EPS rose to $6.98 from $6.42, reflecting higher revenue, improved operating income and a lower tax rate, partly offset by increased interest expense and foreign exchange headwinds. Second-half 2025 pro forma adjusted constant currency revenue grew 4.7%, helped by contribution from the acquired Vascular Intervention business.
For 2026, the company guides GAAP revenue growth of 14.4%–15.4% and pro forma adjusted constant currency revenue growth of 4.5%–5.5%. GAAP EPS from continuing operations is expected at $2.90–$3.20, with adjusted EPS of $6.25–$6.55, reflecting about $90 million of stranded costs after reclassifying divested units as discontinued operations.
In connection with its planned divestitures of the Acute Care, Interventional Urology and OEM businesses, Teleflex’s board approved a multi‑year restructuring plan. The company expects $31–$37 million in restructuring and related charges, mostly cash, and annual pre‑tax savings of $48–$52 million once actions are substantially completed by mid‑2028.
Teleflex corporate VP and Chief HR Officer Cameron P. Hicks received an equity award linked to performance. He acquired 352 shares of common stock underlying performance stock units after performance conditions were met on February 23, 2026, and these units remain subject to vesting on February 28, 2026. After this award, he directly holds 11,759.6473 common shares and indirectly holds 36.0230 shares through a 401(k) trustee.